Diligent Announces Diligent AI to Empower Governance, Risk and Compliance Professionals to Better Manage and Respond to Risk
11.6.2024 15:00:00 EEST | Business Wire | Press release
Diligent, a leading GRC SaaS company, today announced Diligent AI, a powerful set of artificial intelligence capabilities within the Diligent One Platform that enhance how organizations understand, anticipate and mitigate risks. Diligent AI will enable users to identify risks, safeguard data and democratize the decision-making processes, driving resilience and empowering organizations with certainty and clarity like never before.
"Company leaders face a dynamic and evolving risk environment. It’s imperative to turn data into strategic intelligence to anticipate and prevent risks, rather than just respond to them,” said Brian Stafford, President and CEO of Diligent. “Diligent’s AI-enhanced platform is uniquely positioned to connect all aspects of governance, risk and compliance, delivering customized insights to elevate governance and clarify risk.”
Diligent AI helps leaders amplify critical insights while working together across the organization, using risk as a shared language. Leaders can expand resources and achieve greater results through integrated automation, enhance stakeholder communication by tailoring information to board members, chief financial officers, chief risk officers and other executives, and enhance decision making by breaking down information silos across governance, risk and compliance (GRC) functions.
Register for the first session in Diligent’s AI webinar series starting on June 13, where Diligent leaders and experts will discuss Diligent AI capabilities and how they:
Elevate Governance for Boards and Leaders:
- Creating efficient, context-aware summaries of board materials to help directors easily digest information and glean insights.
- Providing AI-powered insights into a company’s ESG focus and self-disclosed risk factors, enabling peer comparison and helping to identify industry trends.
- Quickly assisting with boards-related questions through a 24/7 AI-powered virtual assistant.
Clarify Risk for Audit, Risk and Compliance Teams:
- Simplifying the tedious process of mapping internal controls to regulatory requirements, enabling GRC professionals to efficiently demonstrate compliance.
- Identifying changes between two versions of the same regulation, categorizing them as significant, moderate or minor, enabling users to efficiently update related policies, risks and controls.
- Empowering users to create, edit and troubleshoot data integrations and data analytics scripts using plain language. This brings Diligent's powerful robotics capabilities (also known as ACL Analytics) to a broader audience.
Additional capabilities will be added to Diligent AI over the coming months that empower GRC professionals to better mitigate risks and stay on top of changing regulatory requirements, and help corporate directors govern more effectively amidst escalating risks and information overload.
“Diligent AI adds to the breadth of the Diligent One Platform by enabling leaders to more quickly and effectively respond to risk in a competitive environment,” said Phil Lim, Global AI Champion at Diligent. “Our thoughtful and ethical approach to AI use, guided by industry-leading principles, means customers can feel secure in knowing that AI interacts with their data safely and securely, and only with their prior consent.”
The use of Generative AI in GRC must uphold the highest standards of safety and security, and Diligent has committed to the safe, secure and ethical use of AI through its guiding principles. This ensures users’ data stays their own, generated content is clearly labelled and users must always opt-in before using AI with their data. Learn more about Diligent’s AI Principles here.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611912292/en/
Contacts
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom